Free tools Windows power users keep installed
One-click scans. No signup required.
Intuitive Surgical’s operating growth is strong, but that alone cannot show whether its shares are attractively priced. In the second quarter of 2026, worldwide da Vinci and Ion procedures grew about 16% year over year and the da Vinci installed base reached 11,710 systems. Whether that performance justifies the expectations built into the stock price depends on durable procedure growth, system utilization, margins, and competition—not on one quarter’s results or a single valuation multiple.
What Intuitive Surgical sells—and how the business earns revenue
Intuitive develops, manufactures, and markets the da Vinci surgical system, a platform used to assist surgeons in minimally invasive procedures. Its portfolio also includes Ion, an endoluminal system used in lung biopsy procedures. The company has commercialized multiple generations of da Vinci since 1999; da Vinci 5 was introduced in 2024. Intuitive Surgical’s company overview and its 2025 Form 10-K describe its platforms and business.
System placements are one part of the model, not the whole story. A growing installed base creates an opportunity to perform more procedures, which in turn supports demand for instruments, accessories, and service. The link is not automatic: the number of systems does not establish how intensively hospitals use them or how much revenue and profit each system produces. Investors should distinguish system placements and lease arrangements from procedure activity and recurring product or service revenue.
What the second quarter of 2026 showed
For the quarter ended June 30, Intuitive reported $2.89 billion in revenue, up 19% year over year, and GAAP net income of $818 million, or $2.29 per diluted share, compared with $658 million, or $1.81 per diluted share, in the same quarter of 2025. Worldwide da Vinci and Ion procedures grew approximately 16%; da Vinci procedures rose approximately 15% and Ion procedures approximately 36%. These are reported quarterly results, not a promise that growth will continue at the same rate. Intuitive Surgical’s Q2 2026 results release provides the company’s figures and outlook.
Do these 3 things before closing this tab:
1Clear out junk files and repair common Windows errors2Scan for outdated or missing drivers - takes under a minute3Repair Windows errors before they cause bigger problems#1 Best Overall
- Needle Holder Instrument
- Adson forceps
- Best rated in Professional medical supplies
- Surgical instrument kit
Installed base and system placements
The da Vinci installed base stood at 11,710 systems on June 30, 2026, up 12% from 10,488 a year earlier. Intuitive placed 468 da Vinci systems during Q2 2026, including 246 da Vinci 5 systems; in Q2 2025 it placed 395 systems, including 180 da Vinci 5 systems. These measures capture different things: the installed base is the cumulative footprint, while placements reflect a quarter’s additions. Neither alone establishes the pace of future procedure growth.
Systems revenue
Systems revenue was $685 million in Q2 2026, compared with $575 million in Q2 2025. The company attributed the increase to a larger lease installed base, higher average selling prices for da Vinci systems, and increased placements. This explains the reported movement in that revenue line; it does not, by itself, establish a long-term shift toward recurring revenue or prove that margins will remain stable.
Rank #2
- 18 Pieces in carrying case - Everything you need to practice techniques and dissecting skills. Premium grade stainless steel dissection kit is perfect for students, teachers, artists and other professionals looking to perform their work safely, and effectively.
Why a good business can still pose a valuation problem
A valuation reflects expectations about future results, not just the latest reported quarter. For Intuitive, investors need to consider how long procedure growth can persist, whether newer systems and placements translate into greater use and sales of instruments and services, and what costs are required to develop, manufacture, and support the platforms. If expectations embedded in the share price are high, even a healthy business can disappoint shareholders when growth or margins fall short of those expectations.
A dated market estimate can provide context, but not a verdict. Zacks Investment Research reported a 30.26x forward price-to-earnings estimate for ISRG in an article published September 9, 2026, and compared the company with Medtronic and Stryker. That estimate depends on the share price and earnings forecasts used at the time; it is not an intrinsic-value calculation and should not be treated as the current multiple. Zacks’ September 9, 2026 valuation article gives its dated comparison.
The Tool Desk
Outbyte Driver Updater FREEScan for outdated or missing drivers - takes under a minuteDriver Scan →Outbyte PC Repair FREEClear out junk files and repair common Windows errorsFree Scan →Rank #3
- 82 PCS PREMIUM GERMAN STAINLESS VETERINARY INSTRUMENTS SET -INCLUDE KELLY FORCEPS MOSQUITO FORCEPS CARMALT TOWEL CLAMP MAYO METENBAUM , MAYO SCISSORS-SPAY PACK SET ( CYNAMED BRAND ) ALL IN ONE
- SET INCLUDES: 1 PREMIUM GERMAN GRADE OLSEN HEGAR NEEDLE HOLDER 5.5" ( BLUE ) 1 PREMIUM GERMAN GRADE OLSEN HEGAR NEEDLE HOLDER 5.5" 1 PREMIUM GERMAN GRADE ALLIS TISSUE 4X5 TEETH 7" 4 PREMIUM GERMAN GRADE BACKHAUS TOWEL CLAMP 3.5" 1 PREMIUM GERMAN GRADE SCALPEL HANDLE #3 1 PREMIUM GERMAN GRADE MOSQUITO HEMOSTAT FORCEPS 5" STRAIGHT 2 PREMIUM GERMAN GRADE MOSQUITO HEMOSTAT FORCEPS 5" CURVED 2 PREMIUM GERMAN GRADE KELLY HEMOSTAT FORCEPS 5" STRAIGHT
- 2 PREMIUM GERMAN GRADE KELLY HEMOSTAT FORCEPS 5" CURVED 1 PREMIUM GERMAN GRADE SNOOK OVERIECTOMY HOOK 8" 1 PREMIUM GERMAN GRADE METZENBAUM SCISSORS 6.75" CURVED 1 PREMIUM GERMAN GRADE METZENBAUM SCISSORS 6.75" STRAIGHT 1 PREMIUM GERMAN GRADE MAYO DISSECTING SCISSORS 6.75" CURVED 1 PREMIUM GERMAN GRADE ADSON BROWN FORCEPS 4.75" 9X9TEETH
- 1 PREMIUM GERMAN ROCHESTER CARMALT ARTERY FORCEPS 6.25" CURVED 1 PREMIUM GERMAN ROCHESTER CARMALT ARTERY FORCEPS 6.25" STRAIGHT
- 20 SURGICAL STERILE BLADE #10 20 SURGICAL STERILE BLADE #11 20 SURGICAL STERILE BLADE #15
What investors should weigh
Growth durability
Track procedures by platform, geography, and specialty alongside installed-base growth and new placements. Intuitive reported approximately 18% worldwide da Vinci procedure growth for 2025. Its Q4 2025 release initially forecast 2026 growth of approximately 13% to 15%, but that was historical guidance, not the latest outlook. The Q2 2026 release is the relevant source for current guidance. Quarterly growth rates should not be substituted for a full-year forecast.
Utilization and monetization
Assess whether systems are leased or purchased, how many procedures are performed on them, and how instruments, accessories, and service revenue develop. A larger installed base creates potential for more procedure-linked sales, but realized revenue depends on use and the associated economics. Investors should use reported revenue and utilization data rather than assume each new system contributes equally.
Rank #4
- PROFESSIONAL-GRADE PRECISION: Medical-grade dissection instruments are crafted from certified German stainless steel, precisely weighted and balanced for optimal control during extended procedures, maintaining surgical sharpness and resisting corrosion, purpose-built for college, medical, and veterinary dissection
- COMPREHENSIVE ANATOMY LAB SOLUTION: Complete 46-piece set includes 3 surgical scalpel handles with 20 sterile blades, precision scissors, specialized forceps, tissue clamps, and tissue probes for college, medical, and veterinary dissection studies
- GERMAN ENGINEERING EXCELLENCE: Precision-machined handles fit standard surgical blades for a secure, wobble-free fit during dissection and are compatible with multiple blade contours. The handles use the same certified German stainless steel found in professional surgical settings
- ORGANIZATION & PROTECTION: Premium microfiber lining and individual instrument slots with elastic retention prevent movement during transport and protect fine cutting edges, with specialized compartments for blades and small components
- LIFETIME PROFESSIONAL GUARANTEE: Every BioPrecision Advanced Kit is backed by our unconditional lifetime guarantee. If any instrument fails to perform to professional standards, we will replace it immediately
Margins and execution
Growth also depends on Intuitive’s ability to develop products, supply equipment, and service a growing base while managing costs. Its Q2 2026 filing identifies tariffs, manufacturing, supplier reliance, and transitions in markets where it sells directly among relevant risks. Faster sales do not necessarily mean faster profit growth if costs rise or execution falters.
Competition, regulation, and customer spending
The company’s Q2 2026 Form 10-Q identifies risks involving alternative surgical approaches and competing robotic systems, including domestic competitors in some markets; regulatory requirements and approvals; hospital spending and payer management of procedures; product-development and customer-acceptance uncertainty; staffing; cybersecurity; litigation; and adverse publicity concerning product safety or training. These are disclosed risks, not predictions that any particular event will occur. Intuitive’s SEC filings include the quarterly filing and its risk disclosures.
Best Value
- ITEM: Cynamed-Gold Premium German 82 Pcs Veterinary Instruments Set -Include Kelly Forceps- Mosquito Forceps -Carmalt Forceps -Backhaus Towel Clamp- Mayo Metzenbaum Scissors- All in ONE -SURGICAL DENTAL INSTRUMENT SET
- SET INCLUDES: 1 O.R GERMAN GRADE OLSEN HEGAR NEEDLE HOLDER 5.5" ( GOLD ) 1 O.R GERMAN GOLD HANDLE CARMALT ARTERY FORCEPS 6.25" STRAIGHT 1 O.R GERMAN GOLD HANDLE CARMALT ARTERY FORCEPS 6.25" CURVED 1 O.R GERMAN GRADE ALLIS TISSUE 4X5 TEETH 7" ( GOLD ) 4 O.R GERMAN GRADE BACKHAUS TOWEL CLAMP 3.5" ( GOLD ) 1 O.R GERMAN GRADE SCALPEL HANDLE #3 ( GOLD ) 1 O.R GERMAN GRADE SCALPEL HANDLE #4 ( GOLD )
- 1 O.R GERMAN GRADE MOSQUITO HEMOSTAT FORCEPS 5" STRAIGHT ( GOLD ) 2 O.R GERMAN GRADE MOSQUITO HEMOSTAT FORCEPS 5" CURVED ( GOLD ) 2 O.R GERMAN GRADE KELLY HEMOSTAT FORCEPS 5" STRAIGHT ( GOLD ) 2 O.R GERMAN GRADE KELLY HEMOSTAT FORCEPS 5" CURVED ( GOLD ) 1 O.R GERMAN GRADE SNOOK OVERIECTOMY HOOK 8" ( GOLD ) 1 O.R GERMAN GRADE METZENBAUM SCISSORS 9" CURVED ( GOLD )
- 1 O.R GERMAN GRADE MAYO DISSECTING SCISSORS 6.75" STRAIGHT ( GOLD ) 1 O.R GERMAN GRADE MAYO DISSECTING SCISSORS 6.75" CURVED ( GOLD ) 1 O.R GERMAN GRADE ADSON BROWN FORCEPS 4.75" SERRATED ( GOLD ) 20 SURGICAL STERILE BLADE #10 20 SURGICAL STERILE BLADE #11 20 SURGICAL STERILE BLADE #22
Why headline procedure growth needs context
Aggregate growth can conceal differences between markets and procedure types. In Q2 2026, the company said U.S. procedure growth was led by general surgery—particularly cholecystectomy, hernia repair, and appendectomy—and by gynecological growth. That was partly offset by a high-single-digit decline in U.S. bariatric procedures, which the company said represented approximately 2% of total da Vinci procedures. This is a quarter-specific mix observation, not proof of a long-term trend or its cause.
Placements and procedures can also move at different rates because hospitals make capital-purchase decisions on a different timeline from procedure use. A quarter with more placements need not immediately produce proportional procedure growth, just as a strong procedure quarter does not establish the pace of future placements.
So, is Intuitive Surgical overvalued?
The available operating results establish a large, expanding installed base and continued procedure growth; they do not establish fair value. The 30.26x forward P/E reported by Zacks is a dated estimate, not a present-day multiple or a price target. A premium valuation could be supported if procedure growth, adoption, and system economics remain durable. The same valuation could leave little room for error if growth slows, utilization disappoints, margins compress, or competitive and regulatory pressures increase. Deciding between those possibilities requires current share-price and earnings data, plus an investor’s own assumptions about future performance.
Intuitive listed its Q3 2026 earnings call for October 20, 2026. Because that date was still ahead as of October 3, 2026, the Q2 figures and outlook here do not include subsequent results. Readers evaluating the shares after that call should use the updated filing and guidance rather than carry forward Q2 conditions.
Recommended Free Tools
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
